Heidelberg, Germany
Heidelberg, Germany

Time filter

Source Type

The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.


The present invention relates to the treatment of cancer using a combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent, e.g. a cancer vaccine or a checkpoint inhibitor. Another aspect of the invention is the prognosis of responsiveness of a cancer to the treatment with a combination of a CD95 inhibitor and an immunotherapeutic agent. Further disclosed are preparations and kits for use in these methods.


Patent
Abbvie Inc. and Apogenix | Date: 2017-03-01

Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.


The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.


Patent
Apogenix | Date: 2017-03-08

The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease.


The present invention relates to the treatment of cancer using a combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent, e.g. a cancer vaccine or a checkpoint inhibitor. Another aspect of the invention is the prognosis of responsiveness of a cancer to the treatment with a combination of a CD95 inhibitor and an immunotherapeutic agent. Further disclosed are preparations and kits for use in these methods.


Patent
Apogenix | Date: 2016-12-14

The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.


Patent
Apogenix | Date: 2016-06-03

The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.


Patent
Apogenix | Date: 2016-09-28

The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.


Patent
Apogenix | Date: 2016-04-18

The present invention relates to a composition comprising a mixture of fusion protein isoforms, each fusion protein comprising an extracellular CD95 domain or a functional fragment thereof or an Fc domain or functional fragment thereof, formulations providing such composition in a stable form as well as a method for producing such a composition.

Loading Apogenix collaborators
Loading Apogenix collaborators